|
- IRMS - Nicolae Testemitanu SUMPh
- REVISTE MEDICALE NEINSTITUȚIONALE
- One Health & Risk Management
- One Health & Risk Management 2021
- One Health & Risk Management Vol. 2 No 2, 2021
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/16574
Title: | Evaluarea prezenței anticorpilor anti SARS-COV-2 la donatorii de plasmă convalescentă cu scopul de a argumenta utilizarea lor în tratamentul COVID-19 |
Other Titles: | Assessment of anti SARS-COV-2 antibodies present in convalescent plasma donors aimed at being used in COVID-19 treatment |
Authors: | Spînu, Constantin Cebotari, Svetlana Sajin, Octavian Spînu, Igor Donos, Ala Volneanschi, Ana Gostev, Igor Dopira, Iurie |
Keywords: | COVID-19 treatment;plasma donors;anti SARS-CoV-2;IgG class anti-bodies |
Issue Date: | 2021 |
Publisher: | Asociația de Biosiguranță și Biosecuritate din Republica Moldova |
Abstract: | Introduction. Currently, COVID-19 treatment includes several options, including the use of convalescent plasma. Therefore, the presence of anti-SARS-CoV-2 in blood donors after the clinical recovery of COVID-19, depending on their place of residence, age and the clinical manifestation of the disease is of scientific-practical interest. Material and methods. A total of 119 donors among patients were examined, namely, males aged 18-60 years, having a past history of COVID-19 disease, being confirmed by PCR and treated, showing a negative PCR-based test result, which was performed at least 14 days after clinical recovery. The presence/absence of anti-SARS-CoV-2 was assessed by enzyme-linked immunosorbent assay. Results. The obtained data showed that 87.4% of plasma donors responded to COVID-19 infection by anti-SARS-CoV-2 IgG expression, being predominantly found in the 26-35 age group. Most donors experienced mild and medium clinical forms. It is important to note that all severe clinical manifestations of the infection were followed by formation of anti-SARS-CoV-2 IgG. Urban living environment was predominantly found in convalescent donors (75.0%), which indicates that they are better informed by medical institutions. Conclusions. The study shows that male blood donors aged 18-60 years, subsequently cured and being positive to anti-SARS-CoV-2 IgG can serve as a source of fresh plasma used for the treatment of COVID-19 patients Introducere. Tratamentul COVID-19 include mai multe opțiuni, inclusiv utilizarea plasmei convalescente. Astfel, prezintă un interes științifico-practic existența anticorpilor anti SARS-CoV-2 la donatorii de sânge după recuperarea clinică de COVID-19, în funcție de mediul de trai, de vârstă și de forma de manifestare clinică a bolii. Material și metode. Au fost examinați 119 donatori din rândul pacienților, persoane de sex masculin, cu vârsta de 18-60 ani, cu istoric de boală COVID-19, caz confirmat prin PCR, vindecați, cu rezultat negativ pentru COVID-19, confirmat de testul PCR, la cel puțin 14 zile de la recuperarea clinică. Prezența/absența anti SARS-CoV-2 a fost apreciată prin analiza imunoenzimatică. Rezultate. Datele obținute relevă că 87,4% dintre donatorii de plasmă au răspuns la infecția COVID-19 prin expresia anti SARS-CoV-2 IgG, cu predominare în grupul de vârstă de 26-35 ani. Majoritatea donatorilor au făcut forma clinică ușoară și medie. Este important de menționat că toate formele clinice grave de manifestare a infecției au fost însoțite de producerea de anti SARS-CoV-2 IgG. Donatorii sunt preponderent din mediul urban (75%), fapt ce indică că aceștia sunt mai bine informați de instituțiile medicale. Concluzii. Donatorii de sânge de genul masculin, cu vârsta de 18-60 ani, au avut o imunogeneză activă în urma infectării cu SARS-CoV-2, manifestând un nivel înalt de pozitivitate la anticorpii infecției date. |
metadata.dc.relation.ispartof: | One Health & Risk Management |
URI: | https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/124/79 https://doi.org/10/38045/ohrm.2021.2.08 http://repository.usmf.md/handle/20.500.12710/16574 |
ISSN: | 2587-3466 2587-3458 |
Appears in Collections: | One Health & Risk Management Vol. 2 No 2, 2021
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|